Background. More than 90% of genital warts (GW) cases are caused by human
papillomavirus (HPV) types 6 and 11. The introduction of HPV vaccines necessitates the …

Objective: This study examined the incidence of and healthcare costs attributable to genital
warts within a large US commercially insured, geographically dispersed population …

Objectives To estimate for the first time the incidence and healthcare resource utilisation
associated with genital warts (GW) in Australia prior to the human papillomavirus …

Objectives To estimate the total number of cases of, and cost of care for, genital warts (GWs)
in England, to inform economic evaluations of human papillomavirus vaccination. Methods …

This study evaluated the annual prevalence of anogenital warts (AGW) caused by human
papillomavirus (HPV) and analysed the trend in annual per cent changes (APC) by using …

Background The aim of this study was to assess the cost-effectiveness of human
papillomavirus (HPV) vaccination in addition to the current cervical cancer screening …

[Anogenital warts incidence, medical management and costs in women consulting
gynaecologists in France]. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Background: Little non-clinic-based data are available on incident genital warts rates and
related healthcare use. Goal: The goal of this study was to describe the incidence and …

BACKGROUND: The use of human papillomavirus (HPV) vaccines has been universally
approved for women from age 12 to 25 years, but those older than 16 years receive no …

The human papilloma virus (HPV) vaccine is a new and expensive vaccine potentially
effective in the prevention of a cancer. We reviewed the economic evaluations (EEs) on the …